Derma-Study-Center Friedrichshafen GmbH
- Address
- lock Available on a paid plan
Immune System Diseases
At Derma-Study-Center Friedrichshafen GmbH, clinical research in immune system diseases focuses on chronic inflammatory conditions such as atopic dermatitis and psoriasis. These studies are designed to assess whether new treatments can better control symptoms, reduce disease activity, and improve day-to-day comfort for people living with long-term skin inflammation.
- Testing new treatment options for atopic dermatitis and eczema
- Evaluating therapies for moderate to severe plaque psoriasis
- Assessing treatment effectiveness against persistent inflammatory skin symptoms
The site’s work in this area highlights a strong interest in finding more effective and better-tolerated approaches for patients with ongoing immune-related skin disease.
Skin and Connective Tissue Diseases
Research in skin and connective tissue diseases at this pharmaceutical company site centers on conditions that can strongly affect appearance, comfort, and quality of life, including vitiligo, atopic dermatitis, and plaque psoriasis. The trials aim to improve treatment options and help determine how well emerging therapies work in real-world patient populations.
- Studying treatments for nonsegmental vitiligo
- Comparing therapies for moderate to severe atopic dermatitis
- Exploring new approaches for moderate to severe plaque psoriasis
This research activity reflects a broader effort to advance care for visible, chronic skin disorders through studies that test potential new therapies and evaluate their overall benefit for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Janssen Cilag International1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Derma-Study-Center Friedrichshafen GmbH
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema | Incyte Corp. | Phase II | Not Recruiting | Oct 2023 | Dec 2024 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Jnj-77242113 | 3 | Unknown | 2023-12-19 | 2025-05-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.